The latest investor relations activity record released by MicuRx Pharmaceutical on October 15 shows that the company participated in the analyst meetings of Huashang Fund and Jianxin Pension on October 13, and exchanged views with all parties on the research and development prospects and progress of the company's products.

Regarding the clinical application prospects of MRX-4 after it is launched on the market, the company stated that MRX-4 is a water-soluble prodrug of contezolizumab tablets, which is converted into contezolizumab in the body to exert therapeutic effects. The injectable dosage form has greatly expanded the usage scenarios. According to the "Guiding Principles for the Clinical Application of Antimicrobial Drugs" issued by the National Health Commission in 2015, intravenous administration can quickly reach high drug concentrations. For patients with severe infections and rapid disease progression who require emergency treatment, intravenous administration should be the first choice for clinical use of antibiotics. In addition, the "Guiding Principles for the Clinical Application of Antimicrobial Drugs" points out that for infected patients receiving injectable drugs, when their condition improves after initial injection treatment and they can take it orally, they should be switched to oral administration as soon as possible. The administration of injectable MRX-4/contezolizumab tablets is intravenous sequential oral administration, which is in line with clinical application scenarios.

The company's NDA for MRX-4 (contazolamide sodium for injection) was accepted in May 2025. Its proposed indication is for the treatment of complicated skin and soft tissue infections. This application still requires review, on-site clinical trial inspections, and approval. The timing and outcome of obtaining drug registration approval for this new drug are uncertain.

MRX-5 has completed Phase I clinical trials in healthy subjects in Australia, and Phase I clinical trials in China have officially begun in the first half of 2025. Nineteen healthy subjects have been enrolled in the Phase I clinical trial of MRX-5 in China. The trial is currently progressing normally.

https://finance.eastmoney.com/a/202510163536192192.html